XOMA Royalty Corp 8K

XOMA Royalty Corporation declared quarterly dividends and announced the full redemption of its Series A and B preferred stock and set the contingent value rights record date, all in connection with its pending merger with Ligand Pharmaceuticals.

On June 12, 2026, XOMA Royalty Corporation announced that its board declared quarterly cash dividends on its 8.625% Series A Cumulative Perpetual Preferred Stock and 8.375% Series B Cumulative Perpetual Preferred Stock (represented by depositary shares), and that it will redeem all outstanding shares of both series on July 14, 2026 at $25.00 per share or depositary share, after which dividends will cease to accrue and the preferred stock will no longer be outstanding. The preferred dividends of $0.53906 per Series A share and $0.52344 per Series B depositary share will be paid on or about July 15, 2026 to holders of record as of July 2, 2026, with redemption proceeds to be distributed via DTC. The company stated that this preferred stock redemption is being effected in connection with the pending merger under the April 27, 2026 Agreement and Plan of Merger among XOMA, Ligand Pharmaceuticals Incorporated, and Flex Merger Sub, Inc., and also set July 13, 2026 as the record date for the issuance of one contingent value right per share of common stock as additional merger consideration, entitling holders to potential contingent payments tied to a 75% interest in XOMA Royalty LLC related to the Janssen litigation.

Filing Facts

CIK

791908

Ticker

XOMA

Form

8K

Source Type

sec

Accession

0001193125-26-269734

Alert Tier

7